ClinicalTrials.gg
Active, not recruitingNCT05422482Updated Oct 15, 2024

A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ

A Phase 1 interventional study of GC1123 in Mucopolysaccharidosis II and Hunter Syndrome, sponsored by GC Biopharma Corp. Active, not recruiting at 3 sites in Korea, Republic of. Open to participants aged 18 Months to 18 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by GC Biopharma Corp · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Months to 18 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intracerebroventricular GC1123 in patients with MPS Ⅱ who have central nervous system involvement and are receiving treatment with intravenous drug

Read the detailed description

This study is designed as prospective, open-label, phase I and extension study. Safety, tolerability, pharmacokinetic, and pharmacodynamic properties of repeat-dose treatment of ICV-administered investigational product will be studied in patients undergoing standard treatments.

Patients will undergo cerebrospinal fluid (CSF) reservoir device implantation surgery on their scalps, and the reservoirs will be used to administer GC1123 to the cerebral ventricles monthly (every 28 days). The planned administering dose is 30 mg. After the 2nd dose on the 6th patient, Data and Safety Monitoring Boards (DSMB) will evaluate the safety and tolerability data of GC1123. The planned duration of the sutdy is total about 2 years (phase I and extension)

02

Conditions studied

  • Mucopolysaccharidosis II
  • Hunter Syndrome
03

In context

Mucopolysaccharidosis II

77 studies on the registry are indexed under Mucopolysaccharidosis II; 8 are open to participants now.

This study's planned enrollment of 12 is below the median of 22 across 48 interventional studies indexed under Mucopolysaccharidosis II.

Browse Mucopolysaccharidosis II studies →

Lead sponsor

GC Biopharma Corp is the lead sponsor of 16 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient who has been diagnosed with severe MPS Ⅱ (Hunter syndrome)
  2. Patient, aged 1.5 years (18 months) to 18 years at the time of the screening
  3. Patient who has received and tolerated a minimum of 12 weeks of treatment with weekly intravenous treatment, and who has received 80% of the total planned infusions within that time frame.
  4. Patient who is capable of undergoing neurosurgery, which has been confirmed by neurosurgeons and anesthesiologist.
  5. Patient eligible to execute patient evaluation activities during the clinical trial period, as assessed by the investigator
  6. Patient whose parents or legal representative are willing to participate in this clinical trial and provide written form

Exclusion criteria

Exclusion Criteria:

  1. Patient who has been administered with intrathecal Idursulfase in the past
  2. Patient with a history of bone marrow transplantation or cord blood transplant
  3. Patient with a history of ventriculoperitoneal shunt or other intracranial surgeries
  4. Patient with end-stage multiple organ dysfunction syndrome or other severe diseases
  5. Patient who is exposed to malignant neoplasm
  6. Patient who has received treatment with any drug or device within 30 days prior to study entry
  7. Patient who have experience of or anaphylaxis to ingredients of the investigational product at the time of screening
  8. Patient with a history of bronchotomy/tracheostomy, or patient with acute respiratory disease at the time of screening
  9. Patient who is ineligible to participate in the clinical trial due to laboratory test results or other reasons, as determined by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    GC1123 30mg

    30 mg of IP will be administered every 28 days for all enrolled patients

    Biological: GC1123

Interventions

  • BiologicalGC1123

    ICV-administered Hunterase, Idursulfase-ß

06

What researchers measure

Primary outcomes

  1. Incidence and frequency of serious adverse events (SAEs)

    Incidence and frequency of serious adverse events (SAEs) after administration of ICV-Hunterase (GC1123)

    Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)

  2. Frequency and characteristics (severity, outcome, etc.) of adverse events

    Frequency and characteristics (severity, outcome, etc.) of adverse events after administration of ICV-Hunterase (GC1123)

    Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)

  3. Presence of clinically significant abnormal echocardiography results

    Presence of clinically significant abnormal echocardiography results after administration of ICV-Hunterase (GC1123); phase I only

    Time frame: Week 1 to Phase I study completion (about 26 weeks)

Secondary outcomes

  1. Pharmacokinetic (PK) parameters - Cmax

    Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF

    Time frame: Week 2 to Week 22

  2. Pharmacokinetic (PK) parameters - Tmax

    Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF

    Time frame: Week 2 to Week 22

  3. Pharmacokinetic (PK) parameters - AUClast

    Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF

    Time frame: Week 2 to Week 22

  4. Pharmacokinetic (PK) parameters - AUCinf

    Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF

    Time frame: Week 2 to Week 22

  5. Pharmacokinetic (PK) parameters - t1/2

    Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF

    Time frame: Week 2 to Week 22

  6. Pharmacokinetic (PK) parameters - CL/F (or CL)

    Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF

    Time frame: Week 2 to Week 22

  7. Pharmacokinetic (PK) parameters - Vd/F (or Vd)

    Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF

    Time frame: Week 2 to Week 22

  8. Pharmacokinetic (PK) parameters - Bioavailability (F)

    Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF

    Time frame: Week 2 to Week 22

  9. Pharmacodynamic (PD) parameters - Heparan Sulfate (HS) in CSF

    Pharmacodynamic (PD) parameters of ICV-Hunterase (GC1123)

    Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)

  10. Pharmacodynamic (PD) parameters - Heparan Sulfate (HS) in serum

    Pharmacodynamic (PD) parameters of ICV-Hunterase (GC1123)

    Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)

  11. Pharmacodynamic (PD) parameters - Urine Glycosaminoglycan (GAG)

    Pharmacodynamic (PD) parameters of ICV-Hunterase (GC1123)

    Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)

  12. Presence of anti-drug antibodies (ADAs)

    Presence of anti-drug antibodies (ADAs) in CSF and serum, and neutralizing antibodies of ICV-Hunterase (GC1123)

    Time frame: Approximately every 6 months (Week 2 [baseline], Week 18, Week 26, Week 54, Week 82, Week 110)

Other outcomes

  1. Development Function assessed by Bayley Scales of Infant and Toddler Development-III and/or Kaufman Assessment Battery for Children-II (BSID-III/KABC-II)

    All children will be tested for BSID-III, and children over the age of 3 will be also tested for KABC-II.

    Time frame: Approximately every 6 months (Week 1 [baseline], Week 26, Week 54, Week 82, Week 110)

  2. Adaptive Function assessed by Vineland Adaptive Behavior Scales 2nd Ed. (VABS-II)

    Children under the age of 19 years will be tested for VABS-II.

    Time frame: Approximately every 6 months (Week 1 [baseline], Week 26, Week 54, Week 82, Week 110)

  3. Quality of Life (Survey) assessed by Infant and Toddler Quality of Life Questionnaire (ITQOL) and/or Childhood Health Questionnaire parent form (CHQ-PF50)

    Children from the age of 2 months to 5 years will be tested for ITQOL, and children over the age of 5 will be tested for CHQ-PF50. The test performed during screening will be continued to be performed for each patient throughout the study period.

    Time frame: Approximately every 6 months (Week 1 [baseline], Week 26, Week 54, Week 82, Week 110)

  4. Liver and Spleen volume

    Liver and Spleen volume measured by MRI -phase I only

    Time frame: Week 1 to phase I study completion (about 26 weeks)

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Jun 2027, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2022
First posted
Jun 16, 2022
StartActual
Sep 20, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05422482
Lead sponsor
GC Biopharma Corp
Responsible party
Sponsor
First posted
Jun 16, 2022
Start date
Sep 20, 2022
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 15, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion